published meta-analysis   sensitivity analysis   studies

TD-0903 3mg in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsSingh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] 0.15[0.01; 4.34]Singh (TD-0903 3mg), 202110%13NAnot evaluable deathsdetailed resultsSingh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] 0.15[0.01; 4.34]Singh (TD-0903 3mg), 202110%13NAnot evaluable clinical improvementdetailed resultsSingh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 3.00[0.20; 45.25]Singh (TD-0903 3mg), 202110%13NAnot evaluable clinical improvement (28-day)detailed resultsSingh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 3.00[0.20; 45.25]Singh (TD-0903 3mg), 202110%13NAnot evaluable mechanical ventilationdetailed resultsSingh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] 0.08[0.00; 2.07]Singh (TD-0903 3mg), 202110%13NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 0.38[0.01; 13.93]Singh (TD-0903 3mg), 202110%13NAnot evaluable adverse eventsdetailed resultsSingh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] 0.04[0.00; 1.01]Singh (TD-0903 3mg), 202110%13NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:41 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 963 - roots T: 290